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Available online 12 December 2006Abstract—Several anti-6-substituted 1,3-dioxepan-5-ols were kinetically resolved using an immobilized lipase (Amano PS–C II) in tolu-
ene in the presence of vinyl acetate at 30 C. This approach provided, in some cases, the alcohol and the acetate in high enantiomeric
purity, depending on the nature of the substituent (R = N3, SePh, I, OBn) and the acetal group (unsubstituted or dimethyl). The role
of the size of substituents is also discussed. Enantiopure anti-6-substituted 1,3-dioxepan-5-ols are useful building blocks.
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Figure 2. Structure of Nelﬁnavir.1. Introduction
The importance of chiral 1,2-amino alcohols is evident
since they are often present in many biologically active
compounds. Enantiomerically pure syn- and anti-2-amino-
1,3,4-trihydroxy-butane 1 and syn- and anti-2-azido-
1,3,4-trihydroxy-butane 2 (Fig. 1) would be interesting
chiral building blocks in the synthesis of several important
compounds such as sphingosines,1 FR900482 an antitu-
mour antibiotic,2 kainic acid,3 liposidomycins4 and gly-
comimetics.5 Particularly, such compounds can be used
for the synthesis of C4 unit of Nelﬁnavir, one of the most
potent HIV-protease inhibitors (Fig. 2).6R
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HO OH**
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2: R = N3
3: R = OBn
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Figure 1.Furthermore, (2S,3S)-2-amino-3,4-dihydroxybutyric acid 4
has been used as a synthetic intermediate in the synthesis of
b-lactam antibiotics and phytosiderophores.7
These compounds can be obtained from the chiral pool.
Enantiomerically enriched derivatives of 1 have already0957-4166/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetasy.2006.11.024
* Corresponding author. Tel.: +39 091 596919; fax: +39 091 596825;
e-mail: mgrutt@unipa.itbeen obtained from transformations of isoascorbic
acid,1d,4c ascorbic acid,4b,5b erythrulose8 and from D- or
L-diethyl tartrate.1a
Compounds 1 can also be prepared from chiral aziridino
alcohols obtained by enzymatic method,9 from separation
of a diastereomeric mixture of trans-amino alcohol ob-
tained by meso-epoxide ring opening with chiral amine,6
from asymmetric aminolysis of meso-epoxide using Ti-
(S)-1,1 0-bi-2-naphthoxide complex as chiral catalyst,10
from monoprotected optically active cis-1,4-dihydroxy-
2,3-butene oxide.11 The latter could be generated through
Sharpless asymmetric epoxidation.11 Sharpless asymmetric
aminohydroxylation has also been used employing 2-bu-
tene-1,4-diol derivatives as substrates.12
In addition to compounds 1 and 2, compound 3 is a very
interesting building block too. It can be prepared starting
from the chiral pool using L- or D-tartrate for (S,S)-13 or
(R,R)-enantiomers14 or from D-erythronolactone15 both
for (R,S)- and (S,R)-enantiomers.
Table 2. Enantioselective lipase-catalyzed kinetic resolutions of com-
pounds (±)-8a–ia
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using lipase resolution of secondary alcohols, organocatal-
ysis and organoselenium compounds,16 we were interested
in the stereoselective preparation of compounds 1–3
through enzymatic resolution. Enzymatic resolution of
syn-2-azido-1,3,4-trihydroxy-butane catalyzed by lipases,
both in the transesteriﬁcation mode17 and in the hydrolysis
mode,18 have been reported.
Enzymatic resolution in the transesteriﬁcation mode gave
compound 5 in 33% yield (>99% ee) and compound 6 in
19% yield (94% ee), whereas enzymatic resolution in the
hydrolysis mode gave compound 7 in 30% yield (>99%
ee). These approaches gave high ee values, but low isolated
yields (Fig. 3).N3
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Figure 3.
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toluene, 30 °C OR1 R1
OR1 R1
(±)-anti-8a-i                                     10a-i                     11a-i
Entry Compd t (h) c (%) ee 10 (%) ee 11 (%) Eb
1 (±)-8a 24 26 32 92 38
2 48 35 48 90 31
3 240 52 94 87 51
4 288 57 >99 76 37
5c 24 14 16 99 >200
6c 168 42 65 90 37
7 (±)-8b —d — — — —
8 (±)-8c —e — — — —
9 (±)-8d 3.5 51 >99 96 >200Herein, we report our results on investigations about ki-
netic resolution, mediated by an immobilized lipase (Ama-
no PS–C II), of several racemic anti-6-substituted 1,3-
dioxepan-5-ols as useful precursors of compounds 1–3.10 (±)-8e 168 37 58 >99 >200
11 264 50 >99 >99 >200
12 (±)-8f 1 50 >99 >99 >200
13 (±)-8g 2 44 70 90 40
14 (±)-8h 0.5 50 14 14 1.5
15 (±)-8i 2 50 >99 >99 >200
a Conditions: (±)-8 (0.4 mmol), lipase (50 mg), vinyl acetate (3 equiv),2. Results and discussion
Compounds (±)-anti-8a–i (Table 1) were easily prepared
starting from the proper cyclic epoxide by ring opening
with NaN3, NaSePh, NaI or BnOH.Table 1. The target molecules
O
O
OH
R
O
O
OAc
NHAc
(±)-anti-8a-i                (±)-anti-9
R1 R1
8 R R1
a N3 Me
b NHCbz Me
c NHCOPh Me
d N3 H
e SePh Me
f SePh H
g I H
h OCH2Ph Me
i OCH2Ph H
toluene (0.9 mL), 30 C.
bE = ln[1 c(1 + ee(11))]/ln[1  c(1 ee(11))], c = ee(10)/[ee(10) + ee(11)].
c Solvent: THF.
dDecomposition.
e No reaction.We started our investigation with compound (±)-8a using
PS–C II lipase in toluene in the presence of vinyl acetate.
The resolution of (±)-8a was slow. After 24 h, the conver-
sion was 26% and the ee value of ester 11a was 92% (Table
2, entry 1). After 48 h the conversion was 35% and the ee
value of 11a was 90% (entry 2). The reaction was stoppedafter 240 h and the conversion was 52%. Alcohol 10a was
obtained in 94% ee and ester 11a in 87% ee (entry 3). We
carried out the reaction again and stopped it when alcohol
10a was enantiomerically pure (57% conversion, entry 4).
Resolution in THF gave a lower conversion than in toluene
after 24 h (entry 5). Resolution in THF gave similar results,
about ee values, at higher conversion (entry 6). Using Can-
dida antarctica lipase (Novozym 435), no selectivity was
observed after 24 h (4% ee).In order to improve the enantiopreference, we decided to
follow two diﬀerent strategies. The ﬁrst was to study the
enzymatic resolution of compounds (±)-8b,c having a lar-
ger R group than azido group and R1 = Me. The second
one was to keep the azido substituent (R = N3) and to
put a smaller acetal substituent [R1 = H; (±)-8d]. We also
prepared N,O-diacetyl compound 9 in order to study its
alcoholysis.19
First we prepared the Cbz derivative (±)-8b, but no enzy-
matic resolution was carried out since this product gave,
after 1 h, a complex and inseparable mixture.6b No resolu-
tion was observed with compound (±)-8c. Also the conver-
sion of N,O-diacetyl compound (±)-9 was very poor even
after several days.
We then turned our attention to compound (±)-8d. The
resolution of this molecule was very fast compared to
(±)-8a. Indeed, after 3.5 h we obtained a 51% conversion.
Moreover, the enantiopreference was high (E > 200) giving
ester 11d in 96% ee and alcohol 10d in >99% ee (entry 9).
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Scheme 1. Reagents and conditions: (a) PS-on-Celite, i-Pr2O, vinyl
acetate, 30 C.
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3130 M. Gruttadauria et al. / Tetrahedron: Asymmetry 17 (2006) 3128–3134cis-1,2-Amino alcohols can be prepared starting from anti-
b-hydroxy selenides through displacement of the phenyl-
selenonyl group, following the procedure developed
by Tiecco.20 For this reason, we investigated the
enzymatic resolution of compound (±)-8e.
Compound (±)-8e reacted slowly. The reaction was com-
plete after 264 h. However, the resolution was excellent
(>99%, entry 11). This result conﬁrmed our hypothesis that
with larger R groups better ee values could be reached.
However, the reaction times are long.
Resolution of the less hindered compound (±)-8f gave
enantiopure alcohol 10f and ester 11f in a very short time
(1 h, entry 12). In order to have a diﬀerent leaving group,
we decided to use an iodine atom instead of the phenylse-
leno group. Since an iodine atom is similar in size to the
azido group, we investigated resolution of compound
(±)-8g, which as compound (±)-8d, does not have the bulk-
ier dimethyl acetal group. In this case a lower E value com-
pared with compound (±)-8d was obtained. Indeed, after a
44% conversion ester 11g was obtained in 90% ee (entry
13). The use of other lipases, such as C. antarctica lipase
(Novozym 435) or Candida rugosa lipase, gave poor results.
For instance, with the latter lipase, the ee value of 11g was
30% after a 24% conversion.
Resolution of benzyloxy derivative (±)-8h gave an unex-
pected result (entry 14). Indeed, the reaction was very fast,
being complete in 30 min and giving both alcohol 10h and
ester 11h with very low ee value (14%). In order to improve
the enantiopreference, we carried out the resolution of
compound (±)-8i. In this case, as for (±)-8d and (±)-8f,
the enantiopreference was excellent giving both enantio-
meric pure alcohol 10i and ester 11i (entry 15).
The enantiomeric excess values were determined by HPLC
using a Chiracel OD-H chiral column and n-hexane/i-pro-
panol as eluent (Table 3).Table 3. HPLC retention times of compounds 10a–i and 11a–i
Compd tR (min) Eluent
a,b Compd tR (min) Eluent
a,b
(5S,6R)-10a 17.24 98/2 (5R,6R)-11f 6.36c 90/10
(5R,6S)-10a 13.82c 98/2 (5S,6S)-11f 6.71 90/10
(5S,6R)-11a 5.42c 98/2 (5R,6R)-10g d —
(5R,6S)-11a 6.20 98/2 (5S,6S)-10g d —
(5R,6S)-10d 10.90c 95/5 (5R,6R)-11g 7.14c 98/2
(5S,6R)-10d 11.65 95/5 (5S,6S)-11g 8.67 98/2
(5S,6R)-11d 16.84c 98/2 (5R,6R)-10h 24.15 98/2
(5R,6S)-11d 17.53 98/2 (5S,6S)-10h 25.45c 98/2
(5R,6R)-10e 20.78 98/2 (5R,6R)-11h 10.29c 98/2
(5S,6S)-10e 27.61c 98/2 (5S,6S)-11h 10.95 98/2
(5R,6R)-11e 8.15c 98/2 (5R,6R)-10i 49.55 98/2e
(5S,6S)-11e 8.63 98/2 (5S,6S)-10i 53.46c 98/2e
(5R,6R)-10f 8.67 90/10 (5R,6R)-11i 23.51c 98/2e
(5S,6S)-10f 10.89c 90/10 (5S,6S)-11i 26.18 98/2e
a n-Hexane/i-propanol.
b Flow 1 mL/min.
cMajor enantiomer.
d Determined as ester.
e Flow 0.6 mL/min.The conﬁguration of the products was assigned by analogy
with resolution of compound (±)-12, which was resolved
using the same lipase (lipase PS on Celite; Scheme 1).21
In the cases of compounds 10h and 11h, which were poorly
resolved, conﬁguration was tentatively assigned since such
compounds showed the same elution order and Cotton
eﬀect of compounds 10i and 11i.When considering substrates having the dimethyl acetal
group, the best resolution was obtained with R = SePh.
With the less bulky azido group, the resolution was slightly
less good. Despite the bulkiness of the benzyloxy substitu-
ent, compound (±)-8h showed very poor selectivity, prob-
ably because of the free rotation of such a group. The low
enantiopreference observed is in agreement with the fact
that the CH2 group can also be ﬁtted as a medium sized
substituent into the stereoselective pocket of the enzyme,
whereas the dimethyl acetal group acts as a large substitu-
ent (Fig. 4).(±)-anti-8h
Figure 4. Size of substituents.Following Ema’s model,22 the medium group should be ﬁt-
ted into the stereoselectivity pocket, whereas the large one
is directed towards the external solvent (Fig. 5). On the
grounds of simple computer molecular models, we can rea-
sonably estimate that the size of the dimethyl group is able
to produce an eﬀective steric hindrance for the penetrationM
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Figure 5. Ema’s model.
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substituent too.23
In compounds 8a and 8e, the azido and the phenylseleno
groups must act as large groups. Indeed, it is not possible
to ﬁnd a less hindered conformation. For these substrates,
the portion of the molecule containing the dimethylacetal
group was forced to be the medium one, causing a low
reaction rate because of the steric repulsion.
Indeed, when the dimethyl acetal group was removed the
reaction rates were high giving excellent enantiopreference
for R = SePh, OCH2Ph and N3. The diﬀerence between N3
and I could be ascribed to the higher polarizability of the
iodine atom.
Finally, we carried out a simple manipulation. Compound
10i was oxidized using stabilized 2-iodoxybenzoic acid24 to
give a protected form of (S)-erythrulose (Scheme 2).a
O
O
O
OBn
10i                                           15
O
O
OH
OBn
Scheme 2. Reagents and conditions: (a) 2-iodoxybenzoic acid, ethyl
acetate, 75 C, 91%.Compound 15 is a valuable building block that is currently
used in our laboratory as a starting material for stereoselec-
tive transformations.3. Conclusion
In conclusion, useful enantiopure building blocks have
been obtained by enzymatic resolution of racemic anti-6-
substituted 1,3-dioxepan-5-ols. Excellent resolutions were
obtained with large R substituent (PhSe). With the smaller
N3 substituent, excellent resolution was observed with
R1 = H. When R1 = Me the enantiopreference was lower
because of the steric hindrance caused by the portion of
the molecule containing the dimethyl acetal group. The io-
dine substituent (R = I) did not give excellent results even
with the unsubstituted acetal. Finally, the benzyloxy substi-
tuent may also act as a medium substituent giving a low
enantiopreference when the dimethylacetal group was pres-
ent, whereas it acts as a large substituent when the dimethyl
group was absent giving an excellent resolution. These
compounds are precursors of compounds 1–3, but other
simple manipulations can be carried out. For example, oxi-
dation of compound 10i gave a protected form of (S)-
erythrulose.4. Experimental
4.1. General
The NMR spectra were recorded on a Bruker AC–E series
250 MHz or 300 MHz spectrometer using CDCl3 as sol-
vent. FT-IR spectra were registered with a Shimadzu FTIR8300 infrared spectrophotometer. Carbon and hydrogen
contents were determined by combustion analysis in a
Fisons EA 1108 elemental analyzer. Optical rotations were
measured in chloroform on a Jasco P1010 polarimeter.
Chiral HPLC was performed using a Shimadzu LC-
10AD pump with a SPD-M10A UV detector and Daicel
column (OD-H). Compounds (±)-anti-8a–i were prepared
starting from the proper cyclic epoxide. 2,2-Dimethyl-1,3-
dioxepan-5,6-oxirane and 1,3-dioxepan-5,6-oxirane were
obtained by epoxidation6a of 2,2-dimethyl-1,3-dioxep-5-en
or dimethyl-1,3-dioxep-5-en. Epoxide ring opening was
carried out with NaN3, NaSePh, NaI or BnOH.
25 Com-
pounds (±)-anti-8b–c and (±)-anti-9 were prepared after
reduction of the azido group with Ni–Raney and
protection.
4.2. Enzymatic resolution procedure
To a solution of alcohol (±)-8 (0.4 mmol) in toluene
(0.9 mL) at 30 C, vinyl acetate (1.2 mmol) and PS–C II
lipase (50 mg) were added. The reaction was monitored
by HPLC, then taken up with diethyl ether, ﬁltered and the
solvent removed under reduced pressure. The residue was
checked by NMR, then puriﬁed by silica gel chromatogra-
phy using light petroleum/ethyl acetate as eluent.
4.2.1. (5R,6S)-6-Azido-2,2-dimethyl-1,3-dioxepan-5-ol 10a.
½a27D ¼ þ91:9 (c 0.40, CHCl3); >99% ee. 1H NMR
(250 MHz): d 1.34 (s, 6H), 2.87 (br s, 1H, OH), 3.36–3.43
(m, 1H), 3.55–3.74 (m, 3H), 3.80–3.90 (m, 2H); 13C
NMR (62.5 MHz): d 24.2, 24.6, 58.9, 61.4, 64.3, 71.2,
101.9. IR (liquid ﬁlm) 3423, 2108, 1452, 1375 cm1. Anal.
Calcd for C7H13N3O3: C, 44.91; H, 7.00. Found: C,
44.78; H, 7.13.
4.2.2. (5S,6R)-6-Azido-2,2-dimethyl-1,3-dioxepan-5-yl acet-
ate 11a. ½a22D ¼ 43:3 (c 0.49, CHCl3); 93% ee. 1H
NMR (250 MHz): d 1.34 (s, 6H), 2.10 (s, 3H), 3.49–3.54
(m, 1H), 3.63–3.85 (m, 4H), 4.76–4.82 (m, 1H); 13C
NMR (62.5 MHz): d 20.9, 24.1, 24.3, 59.6, 59.7, 62.4,
73.6, 101.7, 169.7. IR (liquid ﬁlm) 2112, 1745, 1454,
1372 cm1. Anal. Calcd for C9H15N3O4: C, 47.16; H,
6.60. Found: C, 47.32; H, 6.71.
4.2.3. (±)-anti-Benzyl 6-hydroxy-2,2-dimethyl-1,3-dioxepan-
5-yl carbamate 8b. To a solution of (±)-anti-6-amino-2,2-
dimethyl-1,3-dioxepan-5-ol (98 mg, 0.608 mmol) in metha-
nol (1.2 mL), Na2CO3 (0.73 mmol) was added. The mixture
was cooled at 0 C, then benzyl chloroformate (85 lL,
0.73 mmol) was slowly added. The mixture was stirred
for 2 h at room temperature, then ﬁltered and the solvent
removed under reduced pressure. The residue was puriﬁed
by column chromatography using light petroleum/ethyl
acetate 2/1 as eluent. Yield 65%. 1H NMR (250 MHz): d
1.33 (s, 3H), 1.36 (s, 3H), 3.28 (s, 1H, OH), 3.49 (ddd,
J = 12.7, 2.2 and 2.2 Hz, 1H), 3.51–3.81 (m, 4H), 4.03 (d,
J = 12.7 Hz, 1H), 5.11–5.17 (m, 2H), 5.55 (d, J = 7.4 Hz,
1H), 7.33–7.40 (m, 5H).
4.2.4. (±)-anti-N-(6-Hydroxy-2,2-dimethyl-1,3-dioxepan-5-
yl)-benzamide 8c. A solution of benzoyl chloride
(109 lL, 0.943 mmol) in dichloromethane (1 mL) was
3132 M. Gruttadauria et al. / Tetrahedron: Asymmetry 17 (2006) 3128–3134slowly added to a solution of (±)-anti-6-amino-2,2-di-
methyl-1,3-dioxepan-5-ol (152 mg, 0.943 mmol) and NaH-
CO3 (1.13 mmol) in water (1.6 mL). The mixture was
stirred for 2 h at room temperature, then water was added
(15 mL) and the solution extracted with dichloromethane
(3 · 15 mL) and brine (1 · 15 mL). The organic solvent
was removed under reduced pressure to give pure com-
pound 8c (80%). Mp 146 C. 1H NMR (300 MHz): d 1.35
(s, 3H), 1.36 (s, 3H), 3.54 (dd, J = 12.4 and 3.9 Hz, 1H),
3.64 (dd, J = 13.1 and 3.9 Hz, 1H), 3.76–3.81 (m, 2H),
4.11–4.16 (m, 2H), 4.19 (br s, 1H, OH), 6.98 (d,
J = 7.7 Hz, 1H), 7.35–7.51 (m, 3H), 7.74–7.77 (m, 2H);
13C NMR (75 MHz): d 24.8, 25.2, 54.8, 59.7, 62.3, 70.6,
102.3, 127.4, 128.9, 132.1, 134.5, 167.7. IR (nujol) 3382,
3289, 1638, 1626, 1554 cm1. Anal. Calcd for
C14H19NO4: C, 63.38; H, 7.22. Found: C, 63.51; H, 7.33.
4.2.5. (5R,6S)-6-Azido-1,3-dioxepan-5-ol 10d. Mp 44–
46 C; ½a23D ¼ þ50:8 (c 0.48, CHCl3); >99% ee. 1H NMR
(250 MHz): d 2.98 (br s, 1H, OH), 3.48–3.54 (m, 1H),
3.67–3.90 (m, 5H), 4.71 (d, J = 4.5 Hz, 1H), 4.74 (d,
J = 4.5 Hz, 1H); 13C NMR (62.5 MHz): d 63.7, 64.8,
65.7, 71.8, 94.1. IR (liquid ﬁlm) 3432, 2104, 1457 cm1.
Anal. Calcd for C5H9N3O3: C, 37.74; H, 5.70. Found: C,
37.99; H, 5.60.
4.2.6. (5S,6R)-6-Azido-1,3-dioxepan-5-yl acetate 11d.
½a23D ¼ 40:35 (c 0.49, CHCl3); 96% ee. 1H NMR
(250 MHz): d 2.11 (s, 3H), 3.63 (ddd, J = 6.1, 6.1 and
2.9 Hz, 1H), 3.71–3.82 (m, 2H), 3.84 (dd, J = 13.7 and
3.0 Hz, 1H), 3.93 (dd, J = 12.5 and 3.0 Hz, 1H), 4.73 (d,
J = 4.7 Hz, 1H), 4.76 (d, J = 4.7 Hz, 1H), 4.87 (ddd,
J = 6.0, 6.0 and 3.1 Hz, 1H); 13C NMR (62.5 MHz): d
20.8, 62.8, 64.0, 64.5, 73.9, 94.4, 169.7. IR (liquid ﬁlm)
2107, 1735, 1374 cm1. Anal. Calcd for C7H11N3O4: C,
41.79; H, 5.51. Found: C, 41.98; H, 5.62.
4.2.7. (5S,6S)-2,2-Dimethyl-6-(phenylseleno)-1,3-dioxepan-
5-ol 10e. ½a26D ¼ þ17:4 (c 1.02, CHCl3); >99% ee. 1H
NMR (300 MHz): d 1.36 (s, 6H), 2.81 (d, J = 5.4 Hz, 1H,
OH), 3.19–3.23 (m, 1H), 3.61–3.71 (m, 2H), 3.83 (dd,
J = 12.8 and 6.1 Hz, 1H), 4.08–4.16 (m, 2H), 7.27–7.31
(m, 3H), 7.56–7.60 (m, 2H); 13C NMR (75 MHz): d 24.5,
24.7, 51.7, 61.2, 62.8, 71.6, 101.6, 127.7, 128.3, 129.2,
134.3. IR (liquid ﬁlm) 3420, 1580, 1477, 1437, 1373 cm1.
Anal. Calcd for C13H18O3Se: C, 51.83; H, 6.02. Found:
C, 51.70; H, 6.20.
4.2.8. (5R,6R)-2,2-Dimethyl-6-(phenylseleno)-1,3-dioxepan-
5-yl acetate 11e. ½a26D ¼ 29:8 (c 1.47, CHCl3); >99% ee.
1H NMR (250 MHz): d; 13C NMR (62.5 MHz): d 1.35 (s,
6H), 2.07 (s, 3H), 3.25–3.35 (m, 1H), 3.69–3.84 (m, 2H),
4.07–4.17 (m, 2H), 4.90–4.96 (m, 1H), 7.26–7.31 (m, 3H),
7.57–7.63 (m, 2H). IR (liquid ﬁlm) 1738, 1580, 1480,
1437, 1371 cm1. Anal. Calcd for C15H20O4Se: C, 52.48;
H, 5.87. Found: C, 52.60; H, 5.99.
4.2.9. (5S,6S)-6-(Phenylseleno)-1,3-dioxepan-5-ol 10f. Mp
54–55 C. ½a26D ¼ þ4:0 (c 0.95, CHCl3); >99% ee. 1H
NMR (300 MHz): d 3.10 (br s, 1H, OH), 3.42–3.52 (m,
1H), 3.97–4.03 (m, 2H), 4.14 (dd, J = 12.5 and 6.3 Hz,
1H), 4.33–4.41 (m, 2H), 4.97 (d, J = 4.5 Hz, 1H), 5.00 (d,J = 4.5 Hz, 1H), 7.50–7.55 (m, 3H), 7.78–7.81 (m, 2H);
13C NMR (75 MHz): d 51.6, 65.8, 66.7, 72.0, 94.1, 127.6,
128.0, 129.3, 134.6. IR (nujol) 3345 cm1. Anal. Calcd
for C11H14O3Se: C, 48.36; H, 5.17. Found: C, 48.52; H,
5.30.
4.2.10. (5R,6R)-6-(Phenylseleno)-1,3-dioxepan-5-yl acetate
11f. ½a25D ¼ 15:0 (c 1.06, CHCl3); >99% ee. 1H NMR
(300 MHz): d 2.00 (s, 3H), 3.27–3.31 (m, 1H), 3.77–3.84
(m, 2H), 4.02 (dd, J = 12.6 and 2.3 Hz, 1H), 4.14 (dd,
J = 12.3 and 2.4 Hz, 1H), 4.66 (d, J = 4.5 Hz, 1H), 4.72
(d, J = 4.5 Hz, 1H), 4.92–4.97 (m, 1H), 7.19–7.25 (m,
3H), 7.50–7.53 (m, 2H); 13C NMR (75 MHz): d 21.0,
48.0, 65.7, 65.8, 74.3, 94.3, 127.8, 127.9, 129.1, 134.5,
169.9. IR (liquid ﬁlm) 1733, 1578 cm1. Anal. Calcd for
C13H16O4Se: C, 49.53; H, 5.12. Found: C, 49.21; H, 5.01.
4.2.11. (5S,6S)-6-Iodo-1,3-dioxepan-5-ol 10g. ½a24D ¼þ14:4 (c 0.55, CHCl3); 70% ee. 1H NMR (250 MHz): d
3.26 (br s, 1H, OH), 3.66–4.13 (m, 6H), 4.76–4.78 (m,
2H); 13C NMR (62.5 MHz): d 36.5, 66.0, 67.0, 75.5, 77.2,
94.0. IR (liquid ﬁlm) 3425, 1452 cm1. Anal. Calcd for
C7H13IO3: C, 30.90; H, 4.82. Found: C, 30.99; H, 4.90.
4.2.12. (5R,6R)-6-Iodo-1,3-dioxepan-5-yl acetate 11g.
½a23D ¼ 41:7 (c 0.79, CHCl3); 90% ee. 1H NMR
(250 MHz): d 2.12 (s, 3H), 3.72 (dd, J = 12.2 and 7.0 Hz,
1H), 3.85 (dd, J = 12.5 and 8.0 Hz, 1H), 3.97 (dd,
J = 12.2 and 3.1 Hz, 1H), 4.03–4.15 (m, 2H), 4.79 (d,
J = 4.5 Hz, 1H), 4.82 (d, J = 4.5 Hz, 1H), 5.09–5.15 (m,
1H); 13C NMR (62.5 MHz): d 21.3, 30.6, 65.4, 67.7, 77.3,
94.6, 170.0. IR (liquid ﬁlm) 1735, 1369 cm1. Anal. Calcd
for C9H15IO4: C, 34.41; H, 4.81. Found: C, 34.61; H, 4.99.
4.2.13. 6-(Benzyloxy)-2,2-dimethyl-1,3-dioxepan-5-ol 10h.
½a25D ¼ þ2:0 (c 1.26, CHCl3); 14% ee. 1H NMR
(300 MHz): d 1.29 (s, 3H), 1.36 (s, 3H), 2.78 (br s, 1H,
OH), 3.37–3.48 (m, 2H), 3.57 (dd, J = 11.5 and 4.3 Hz,
1H), 3.65 (dd, J = 7.6 and 7.6 Hz, 1H), 3.87 (dd,
J = 6.6 Hz, 1H), 4.16 (ddd, J = 6.6, 6.6 and 6.6 Hz, 1H),
4.57 (d, J = 11.9 Hz, 1H), 4.63 (d, J = 11.9 Hz, 1H),
7.14–7.27 (m, 5H); 13C NMR (75 MHz): d 25.1, 26.1,
61.4, 65.3, 72.4, 76.3, 79.2, 109.0, 127.4, 127.6, 128.1,
138.0. IR (liquid ﬁlm) 3457, 1454, 1380, 1370 cm1. Anal.
Calcd for C14H20O4: C, 66.65; H, 7.99. Found: C, 66.80;
H, 8.14.
4.2.14. 6-(Benzyloxy)-2,2-dimethyl-1,3-dioxepan-5-yl ace-
tate 11h. ½a26D ¼ 2:6 (c 0.69, CHCl3); 14% ee. 1H
NMR (300 MHz): d 1.29 (s, 3H), 1.35 (s, 3H), 1.97 (s,
3H), 3.47–3.54 (m, 2H), 3.60–3.68 (m, 1H), 3.73 (dd,
J = 8.3 and 7.1 Hz, 1H), 3.93 (dd, J = 8.3 and 6.6 Hz,
1H), 4.19–4.27 (m, 1H), 4.62 (d, J = 11.8 Hz, 1H), 4.69
(d, J = 11.8 Hz, 1H), 7.21–7.29 (m, 5H); 13C NMR
(75 MHz): d 20.9, 25.3, 27.3, 63.6, 65.5, 72.9, 76.0, 76.8,
109.5, 127.8, 127.9, 128.4, 138.1, 170.8. IR (liquid ﬁlm)
1742 cm1. Anal. Calcd for C16H22O5: C, 65.29; H, 7.53.
Found: C, 65.50; H, 7.67.
4.2.15. (5S,6S)-6-(Benzyloxy)-1,3-dioxepan-5-ol 10i.
½a30D ¼ þ29:0 (c 0.82, CHCl3); >99% ee. 1H NMR
(300 MHz): d 2.70 (br s, 1H, OH), 3.26–3.29 (m, 1H),
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(d, J = 12.0 Hz, 1H), 4.45 (d, J = 12.0 Hz, 1H), 4.52–4.56
(m, 2H), 7.06–7.15 (m, 5H); 13C NMR (75 MHz): d 64.4,
65.6, 71.4, 71.5, 80.3, 94.5, 127.7, 127.8, 128.4, 137.9. IR (li-
quid ﬁlm) 3445, 1454 cm1. Anal. Calcd for C12H16O4: C,
64.27; H, 7.19. Found: C, 64.42; H, 7.27.
4.2.16. (5R,6R)-6-(Benzyloxy)-1,3-dioxepan-5-yl acetate
11i. ½a31D ¼ 11:7 (c 0.88, CHCl3); >99% ee. 1H NMR
(300 MHz): d 2.00 (s, 3H), 3.42–3.47 (m, 1H), 3.74–3.80
(m, 3H), 3.89 (dd, J = 12.9 and 2.2 Hz, 1H), 4.60 (s, 2H),
4.69 (d, J = 4.6 Hz, 1H), 4.72 (d, J = 4.6 Hz, 1H), 4.90–
4.94 (m, 1H), 7.21–7.28 (m, 5H); 13C NMR (75 MHz): d
20.11, 63.6, 63.7, 70.5, 72.1, 76.8, 93.7, 126.9, 127.4,
136.9, 169.1. IR (liquid ﬁlm) 1739, 1454, 1371,
1238 cm1. Anal. Calcd for C14H18O5: C, 63.15; H, 6.81.
Found: C, 63.25; H, 6.98.
4.2.17. (±)-anti-6-Acetamido-2,2-dimethyl-1,3-dioxepan-5-yl
acetate 9. To a solution of (±)-anti-6-amino-2,2-di-
methyl-1,3-dioxepan-5-ol (125 mg, 0.775 mmol) in N,N-
dimethylformamide (0.5 mL), Na2CO3 (1.55 mmol) and
acetic anhydride (1 mL) were added. The mixture was stir-
red for 2 h at room temperature, then water (20 mL) was
added and the mixture extracted with ethyl acetate
(3 · 15 mL) and brine (1 · 15 mL). The solvent was re-
moved under reduced pressure and the residue puriﬁed
by washing with diethyl ether. Yield 90%. Mp 123 C. 1H
NMR (300 MHz): d 1.36 (s, 3H), 1.38 (s, 3H), 2.03 (s,
3H), 2.11 (s, 3H), 3.49 (dd, J = 12.6 and 4.2 Hz, 1H),
3.72 (d, J = 13.5 Hz, 1H), 3.84 (dd, J = 13.5 and 3.9 Hz,
1H), 4.00–4.08 (m, 2H), 4.72–4.76 (m, 1H), 6.04 (d,
J = 6.9 Hz, 1H); 13C NMR (75 MHz): d 21.5, 23.7, 24.6,
25.2, 51.9, 59.8, 60.4, 72.8, 102.3, 162.7, 169.8. IR (nujol)
3231, 3068, 1736, 1644 cm1. Anal. Calcd for
C11H19NO5: C, 53.87; H, 7.81. Found: C, 53.60; H, 7.98.
4.2.18. (S)-6-Benzyloxy-1,3-dioxepan-5-one 15. To a solu-
tion of compound 10i (300 mg, 1.34 mmol) in ethyl acetate
(9.5 mL) was added 2-iodoxybenzoic acid (1.2 equiv, 1.0 g)
and the mixture heated at 75 C for 4.5 h. After cooling at
room temperature, the mixture was ﬁltered and the solid
washed with ethyl acetate. The ﬁltrate was evaporated un-
der reduced pressure, then puriﬁed by column chromato-
graphy using light petroleum ether/ethyl acetate 5/1 as
eluent to give compound 15. Yield 91%. ½a26D ¼ 28:10 (c
0.33, CHCl3). Mp 67–68 C. 1H NMR (250 MHz): d 3.81
(dd, J = 12.3 and 6.6 Hz, 1H), 3.94 (d, J = 17.8 Hz, 1H),
4.04 (dd, J = 12.3 and 7.4 Hz, 1H), 4.28 (d, J = 17.8 Hz,
1H), 4.41 (d, J = 11.7 Hz, 1H), 4.70–4.81 (m, 3H), 4.93
(d, J = 5.6 Hz, 1H), 7.30–7.37 (m, 5H); 13C NMR
(62.5 MHz): d 68.7, 72.3, 72.8, 82.5, 96.2, 127.9, 128.0,
128.5, 137.3, 208.4. IR (nujol) 1734, cm1. Anal. Calcd
for C12H14O4: C, 64.85; H, 6.35. Found: C, 64.90; H, 6.41.Acknowledgements
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